# TriSalus Life Sciences share price today (TriSalus Life Sciences, Inc., TLSI)

> TriSalus Life Sciences, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. TLSI · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/tlsi

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.48 (−26.6% in a year)
- Revenue (Jun 2026): $11.4 M (+1.7% on a year ago)
- Profit (Jun 2026): −$9.2 M
- Operating margin: −86.0% (−20.6 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the TriSalus Life Sciences share price today? TriSalus Life Sciences, Inc.'s share price was $3.48 at the close on 3 November 2026. That is 20.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $7, and at that close it sat 17% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 1 year the share price moved −29% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does TriSalus Life Sciences pay? TriSalus Life Sciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is TriSalus Life Sciences on? TriSalus Life Sciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is TriSalus Life Sciences profitable? TriSalus Life Sciences, Inc. posted a net loss of $9.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $69.7 M. That loss is 80.5% of the quarter's revenue. The same quarter a year earlier lost $9.0 M. 11 of the last 12 reported quarters were loss-making. ## How much revenue does TriSalus Life Sciences make, and is it growing? TriSalus Life Sciences, Inc. reported $11.4 M of revenue in the Jun 2026 quarter, +1.7% on the same quarter a year earlier. Over 4 years it has grown 52.3% a year on average. The last full year, FY25, came in at $45.2 M. The last four reported quarters add to $45.1 M. FY25 revenue was $45.2 M, +53.4% on the year before. Recent pace: the last four quarters grew +29.0% on average, against 52.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +25.2%, against +35.0% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does TriSalus Life Sciences keep? TriSalus Life Sciences, Inc.'s operating margin was −86.0% in the Jun 2026 quarter, 20.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between −293.9% and −59.7%. The latest quarter is within that range. Why the margin moved: operating margin changed −20.6 percentage points on the year while gross margin changed +2.9 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is TriSalus Life Sciences' profit turning into cash? TriSalus Life Sciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $18.0 M of cash, against −$69.7 M of profit. After $918 K of spending on assets, free cash was −$18.9 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does TriSalus Life Sciences' cash go? TriSalus Life Sciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.9 M on assets over the last 3 years. Averaged over those years that is 1.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.9 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is TriSalus Life Sciences' P/E ratio, and how does it compare with its own history? TriSalus Life Sciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values TriSalus Life Sciences, Inc. at 4.7× its FY25 revenue of $45.2 M. The P/E comes back here once profit turns positive. ## Is the TriSalus Life Sciences business getting better or worse? TriSalus Life Sciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does TriSalus Life Sciences earn on its capital? TriSalus Life Sciences, Inc. earned a ROE of 206% in FY25. That is up from a low of −93% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −1,311%, a number that says nothing useful about the business. It comes from a −154.3% net margin and 1.28× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −154.3% net margin × 1.28× asset turnover × −1.04× leverage (assets divided by equity) ≈ 205.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does TriSalus Life Sciences have too much debt? TriSalus Life Sciences, Inc. has total debt of $34.4 M against shareholder equity of $6.6 M as of Jun 2026, so its debt is 5.26× its equity. Year by year, that ratio went from −0.16 in FY22 to −1.02 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the TriSalus Life Sciences shareholding pattern? 6.9% of TriSalus Life Sciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is TriSalus Life Sciences from balance-sheet trouble? For TriSalus Life Sciences, Inc., the Z-score is −4.86. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −4.86 is inside the danger zone, so the balance sheet is a real risk. ## How does TriSalus Life Sciences rank in its industry? There is no score against its industry: TriSalus Life Sciences, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is TriSalus Life Sciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to TriSalus Life Sciences in size? TriSalus Life Sciences is the 72nd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: InfuSystem Holdings, Inc., Standard BioTools Inc. and Electromed, Inc. Just below it: RxSight, Inc., Neuronetics, Inc. and Perspective Therapeutics, Inc. ### Medical Devices companies close in size

1. [InfuSystem Holdings, Inc.](https://www.sectoralpha.in/us/stocks/infu) $255 million
2. [Standard BioTools Inc.](https://www.sectoralpha.in/us/stocks/lab) $240 million
3. [Electromed, Inc.](https://www.sectoralpha.in/us/stocks/elmd) $221 million
4. TriSalus Life Sciences, Inc. $214 million
5. [RxSight, Inc.](https://www.sectoralpha.in/us/stocks/rxst) $191 million
6. [Neuronetics, Inc.](https://www.sectoralpha.in/us/stocks/stim) $172 million
7. [Perspective Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/catx) $100 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [American Outdoor Brands, Inc.](https://www.sectoralpha.in/us/stocks/aout) $229 million · Leisure
2. [CF Bankshares Inc.](https://www.sectoralpha.in/us/stocks/cfbk) $228 million · Banks - Regional
3. TriSalus Life Sciences, Inc. $228 million
4. [MBIA Inc.](https://www.sectoralpha.in/us/stocks/mbi) $228 million · Insurance - Specialty
5. [AstroNova, Inc.](https://www.sectoralpha.in/us/stocks/alot) $227 million · Computer Hardware

## What else do people ask about TriSalus Life Sciences? ### What were TriSalus Life Sciences's latest quarterly results? TriSalus Life Sciences, Inc. reported revenue of $11.4 M and a net loss of $9.2 M for the Jun 2026 quarter. Earnings per share were −$0.16. The operating margin was −86.0%, 20.6 percentage points lower than a year earlier (as of 3 November 2026). ### What is TriSalus Life Sciences's market cap? TriSalus Life Sciences, Inc.'s market capitalisation is $214 M at a stock price of $3.48. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is TriSalus Life Sciences performing? TriSalus Life Sciences, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will TriSalus Life Sciences's stock price go up? This page does not forecast TriSalus Life Sciences, Inc.'s stock price. What it shows instead: the stock price is $3.48. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is TriSalus Life Sciences in its business cycle? TriSalus Life Sciences, Inc.'s FY25 operating margin was −59.7%, against a 5-year range of −293.9% to −59.7%: the middle of its own range, neither a peak nor a low. The latest quarter was −86.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the TriSalus Life Sciences story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is TriSalus Life Sciences a stock worth studying right now? What the numbers show: TriSalus Life Sciences, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.